Preoperative PSMA PET/CT as Triage for ePLND in Patients Scheduled for RALP (PrePSMA) - Trial NCT06398613
Access comprehensive clinical trial information for NCT06398613 through Pure Global AI's free database. This phase not specified trial is sponsored by Oslo University Hospital and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Oslo University Hospital
Timeline & Enrollment
N/A
Apr 26, 2024
Dec 31, 2029
Primary Outcome
Difference between Arm A and Arm B in biochemical recurrence (BCR) rate between groups within 2 years after initiation of RALP
Summary
Extended pelvic lymph node dissection (ePLND) is considered the gold standard for nodal
 staging in men with prostate cancer (PCa). The aim of this project is to determine if
 preoperative prostate specific membrane antigen (PSMA) positron emission tomography
 (PET)/computed tomograpy (CT) can safely replace ePLND as a staging method in PCa patients
 undergoing robot-assisted laparoscopic radical prostatectomy (RALP).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06398613
Non-Device Trial